-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9, the National Medical Insurance Administration issued a reply to the recommendation No.
The original text is as follows:
National Medical Security Administration on the Fourth Session of the 13th National People's Congress
Reply to Recommendation No.
Medical Insurance Letter (2021) No.
Representative Lu Qingguo:
Your suggestion on accelerating the entry of Chinese medicines and formula granules into centralized procurement has been received.
1.
In accordance with the decisions and deployments of the Party Central Committee and the State Council, starting from 2018, the National Medical Insurance Bureau, in conjunction with relevant departments, has promoted the reform of the centralized drug procurement system in an orderly manner, and successfully carried out five batches of 218 drug centralized procurement
Your suggestion that proprietary Chinese medicines enter the centralized drug procurement as soon as possible, so that more traditional Chinese medicine manufacturers can participate in the competition fairly, we have policy arrangements and preliminary explorations
Second, the next step to consider
We attach great importance to your suggestion of improving the standard system and accelerating the inclusion of proprietary Chinese medicines and formula granules into centralized procurement
